Advertisement


Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

2024 ASCO Annual Meeting

Advertisement

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
HER2 overexpression breast cancer represents around 20% of patients with metastatic breast cancer. The outcome in recent trials is around 50 to 60 months median overall survival with the first-line therapy being Taxane plus Trastuzumab plus Pertuzumab, and this combination provides around 18 months progression-free survival. In this context, there is a need to improve the outcome of these patients. Trastuzumab Deruxtecan is a new drug, it is an antibody-drug conjugate that targets HER2. This drug has shown efficacy in patients who present with HER2 overexpression metastatic breast cancer, previously treated with Taxane Pertuzumab Trastuzumab. In this context, the question is whether giving Trastuzumab Deruxtecan in the first-line setting could improve the outcome of patients. Before moving to the Phase IV / Phase III, it was necessary to run the Phase I / Phase II to explore the safety and preliminary signal of efficacy. In DESTINY-Breast07 Phase I / Phase II, 75 patients were included in the first-line setting to receive Trastuzumab Deruxtecan. 50 patients were included again in the first-line setting to receive Trastuzumab Deruxtecan plus Pertuzumab. What are the results? The response rate was 76% in patients who received Trastuzumab Deruxtecan single agent, and was 84% in the group of patients who received Trastuzumab Deruxtecan plus Pertuzumab. In terms of progression-free survival, it's too early to conclude. Nevertheless, more than 80% of the patients, whether they were treated with Trastuzumab Deruxtecan or T-DXd plus Pertuzumab, more than 80% of the patients had a progression-free survival more than 12 months. Meaning that the disease is controlled for the vast majority of patients for more than 12 months. Then in terms of subgroup, there was no difference of efficacy according to the expression of hormone receptor or whether the disease was recurrent after adjuvant therapy or de novo. In terms of safety, around 10% of patients presented with ILD, which is lung toxicity. Nevertheless, no toxic death was observed. One toxicity that was moderate, but that was increased with Pertuzumab, was diarrhea, but still the number and the percentage are very small. So what can we say about this study? It's a Phase I / Phase II study that tells us that in the first-line setting, T-DXd or T-DXd plus Pertuzumab, provides encouraging preliminary signal of efficacy, and that was the rationale to start a Phase III trial testing this new drug in the first-line setting as compared to the standard of care, and hopefully will improve the outcome of the patients.

Related Videos

Skin Cancer

Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).

Breast Cancer

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 

Lung Cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).

Palliative Care

Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Advertisement

Advertisement




Advertisement